Syndax Pharmaceuticals

SNDX13F as of Jun 30, 2026 · next update ~Nov 14

Limited coverage

Only 1 fund we track owns this stock, so quarterly sentiment and aggregates may be sparse.

Who's buying SNDX

Top funds mostly added to Syndax Pharmaceuticals in Q2 (Apr⁠–⁠Jun)

Buying:

Funds1InsidersCongress

Top funds
1 of 1 bought more, 0 sold some. Largest: Torray Investment Partners, $2.9M (0% of its portfolio).
Insiders
No buys, 8 sales in 12 months.
Congress
No trades disclosed in the last 12 months.

1 fund$2.9M held0.4% avg. weightQ2: 1 bought / 0 sold

13F reports are a snapshot as of Jun 30, 2026; funds may have traded since. Insiders often sell for personal reasons (taxes, diversification, planned sales).

Share price · market data, not from 13F reports

Q2 2026

Insider trades (Form 4)

Last 2 years · 19 filings

Net buying$6.98M

Date	Insider	Type	Shares	Price	Value
Jul 8, 2026	Michael A Metzger CEO	Sold	32,375	$24.24	$785K
Jun 11, 2026	Nicholas A.j. Botwood CMO	Sold	65,515	$18.07	$1.18M
Jun 1, 2026	Keith A. Goldan CFO	Sold	1,177	$18.99	$22K
Jun 1, 2026	Michael A Metzger CEO	Sold	6,847	$18.99	$130K
Feb 9, 2026	Michael A Metzger CEO	Sold	17,159	$21.03	$361K
Feb 9, 2026	Keith A. Goldan CFO	Sold	3,410	$21.03	$72K
Feb 6, 2026	Michael A Metzger CEO	Sold	7,412	$20.62	$153K
Feb 6, 2026	Keith A. Goldan CFO	Sold	2,082	$20.62	$43K
Sep 8, 2025	Michael A Metzger CEO	Sold	157,307	$16.41	$2.58M
Aug 14, 2025	Dennis Podlesak Director	Sold	57,600	$15.19	$875K
Jul 16, 2025	Keith A. Goldan CFO	Sold	1,296	$9.29	$12K
Jul 16, 2025	Michael A Metzger CEO	Sold	7,534	$9.29	$70K
May 16, 2025	Nicholas A.j. Botwood CMO	Bought	11,765	$9.00	$106K
May 19, 2025	Martin H. Huber Jr. Director	Bought	5,000	$8.99	$45K
May 19, 2025	Keith Katkin Director	Bought	10,000	$9.11	$91K
Mar 4, 2025	Michael A Metzger CEO	Sold	7,814	$15.05	$118K
Feb 10, 2025	Keith A. Goldan CFO	Sold	3,777	$15.50	$59K
Feb 10, 2025	Michael A Metzger CEO	Sold	13,288	$15.50	$206K
Feb 10, 2025	Neil Gallagher President	Sold	4,618	$15.50	$72K